Semaglutide has a study amount, not your amount.
Semaglutide is the ingredient in Wegovy. If you've seen a weight-loss figure and wondered what amount went with it, you're in the right place. We'll follow one study, with its people and its limits, rather than turn that number into a plan.
One study, one reported amount
In the STEP 1 weight study, researchers compared semaglutide 2.4 mg by weekly injection under the skin with placebo, a treatment without the drug. Participants were adults with obesity, or overweight with a weight-related condition, without diabetes. Both groups had lifestyle support.
The semaglutide group lost more weight on average over 68 weeks. The amount tells us what the trial tested. It doesn't tell you where to begin or how to increase treatment.
Reading limit: A reported study amount cannot choose your starting amount or treatment plan.
A tablet is a different conversation
The Wegovy label covers tablets and injections. They contain semaglutide, but they deliver it differently. The ingredient name alone doesn't make their printed amounts a swap.
Milligrams alone let us down here. The product, route, people and outcome matter too. A larger printed number isn't, by itself, evidence of a stronger effect. This study's result describes an injection.
Reading limit: The same ingredient in different forms does not create a simple conversion.
The uncomfortable bits count too
The safety review describes nausea, vomiting, diarrhea and constipation, as well as gallbladder concerns. An average weight result can't tell you how manageable treatment felt for each person. Side effects belong in the main conversation.
The label's strongest warning concerns thyroid tumors seen in rodents. Whether semaglutide causes them in people is unknown. The label rules it out with a personal or family history of medullary thyroid cancer, a rare thyroid cancer, or MEN 2, a rare inherited condition.
Reading limit: A useful weight result is not evidence that the medicine suits everyone.
Name the product in the next conversation
A licensed U.S. clinician, including through a prescribing telehealth service, can discuss which approved product, if any, fits your health needs. Other medicines, serious stomach problems and pregnancy plans belong in that assessment.
FDA reports dosing errors with unapproved GLP-1 products, including semaglutide. GLP-1 is the gut-hormone system this medicine acts on. Compounded medicines are not FDA-approved. Mixing, measuring or switching products needs medical guidance.
Reading limit: Product choice and personal amounts need an individual medical assessment.